迪拜数字经济商会（迪拜商会旗下三大商会之一）最新发布的2025年度数据显示，在商会的支持下，过去一年有1690家数 字初创企业成功在迪拜完成成立和扩张，同比增长39.7%，其中人工智能企业占比15%，金融科技占12%。迪拜的数字经济需求 与中国企业优势高度匹配。2025年，在迪拜数字商会举办的2025"北极星拓展"大会上，有多家中国初创公司参与项目路演，涵 盖人工智能、医疗科技、工业制造以及绿色能源等领域。 本报讯 （记者韩昱）2月27日，《证券日报》记者获悉，迪拜商会主席卢塔日前发表署名文章。文章显示，2025年迪拜商 会中国企业数量再创新高，中国企业极具韧性和创新性。中国企业在迪拜商贸生态系统中的重要性日益提升，体现在迪拜商会 新会员数量的创纪录增长上。2025年，迪拜商会迎来了1583家新增中国企业，同比增长7%。截至2025年底，超过6400家中国 公司注册为商会活跃会员，广泛分布在批发零售、房地产、建筑和物流等领域。中国在未来导向产业的专业能力与迪拜经济议 程（D33）目标高度契合，为双方在人工智能、先进制造和清洁技术等领域的合作开辟了广阔机遇。 （编辑 张昕） ...

证券研究报告 | 公司点评报告 2026 年 02 月 25 日 汇聚科技（01729.HK） 配售募资注入强劲动能，战略投资及海外扩张加速 TMT 及中小盘/电子 事件：汇聚科技于 2026 年 2 月 20 日发布完成根据一般授权配售新股份公告， 合共 108,000,000 股配售股份，已成功配售予不少于六名承配人，配售价为每 股 15.22 港元，配售事项所得款项净额约为 1,634.5 百万港元。我们点评如下： 强烈推荐（维持） 目标估值：NA 当前股价：17.94 港元 基础数据 | 总股本（百万股） | 2091 | | --- | --- | | 香港股（百万股） | 2091 | | 总市值（十亿港元） | 37.5 | | 香港股市值（十亿港元） | 37.5 | | 每股净资产（港元） | 0.9 | | ROE（TTM） | 23.2 | | 资产负债率 | 74.8% | | 主要股东 | 立讯精密有限公司 | | 主要股东持股比例 | 70.7069% | 股价表现 % 1m 6m 12m 绝对表现 7 76 288 相对表现 8 71 274 资料来源：公司数据、招商证券 -10 ...

Group 1 - The company, Siyu MedTech, is a professional content and research team focused on the medical technology industry [2][3] - The team is looking for a young operational talent who can create content and drive projects to fruition [3][4] - The role involves comprehensive operations including industry events, video production, and content projects [4][6] Group 2 - The position requires interaction with medical device companies, clinical doctors, and investors [5] - Responsibilities include preparing industry events, coordinating with doctors and guests, and supporting on-site execution [6][19] - The ideal candidate should have a background in relevant fields such as medicine, pharmacy, biomedical engineering, or related areas, and possess content and video skills [12][19] Group 3 - The role offers opportunities to engage with industry experts and understand the transition of technology to clinical applications [19] - The company provides competitive compensation, social insurance, and flexible vacation policies [20] - Candidates are encouraged to submit their resumes along with links to their video work [21][22]

Core Viewpoint - The article emphasizes the unique position of the company, SiYu MedTech, as a professional team deeply engaged in the medical technology industry, focusing on producing in-depth content and industry research rather than traditional promotional activities [1]. Group 1: Company Overview - SiYu MedTech was established at the end of 2016 and has been operating for nearly nine years, with aspirations to recruit fresh graduates to join the rapidly evolving medical technology field by 2026 [2]. - The company serves professionals in the medical technology industry, producing specialized content that intersects clinical, technological, and industrial domains [3]. Group 2: Job Responsibilities - The role involves producing in-depth content related to various medical technology sectors, including surgical robotics, ophthalmology, cardiovascular, neurology, orthopedics, medical imaging, and aesthetic technology [3]. - Responsibilities include writing industry white papers, research reports, and systematic column planning, as well as providing content planning and communication support for medical device companies [3][4]. - The company focuses on translating technical language into industry-understandable terms and organizing industry conferences and closed-door discussions [4]. Group 3: Candidate Expectations - The company seeks candidates with a background in fields such as medicine, pharmacy, biomedical engineering, and related disciplines, with a preference for clinical or engineering backgrounds [8]. - Ideal candidates should be able to read and understand English literature, possess strong research skills, and be willing to engage with complex topics and iterative revisions [8]. Group 4: Work Environment and Benefits - The work environment allows for remote working, reducing commuting time and enabling focus on reading, thinking, and writing [13]. - The company offers flexible vacation arrangements, a stable work environment with no history of layoffs, and the opportunity for employees to engage in higher-difficulty projects as their skills grow [13].

Core Viewpoint - Abbott's financial performance for 2025 shows overall revenue and earnings growth, with significant contributions from the medical devices segment, while nutrition and diagnostics face challenges [1][3][22]. Overall Financial Performance - In Q4 2025, Abbott reported total sales of approximately $11.46 billion, with a net profit of $1.78 billion, leading to a diluted EPS of $1.01 and an adjusted EPS of $1.50, slightly above market expectations [4][5]. - For the full year 2025, total sales reached about $44.33 billion, with a diluted EPS of $3.72 and an adjusted EPS of $5.15, achieving double-digit growth [4][21]. Business Segment Breakdown Medical Devices - The medical devices segment continues to be the standout performer, with Q4 sales of $5.68 billion, reflecting a 12.3% year-over-year growth [8][9]. - Growth in this segment is driven by products related to cardiac rhythm management, electrophysiology, and chronic disease management solutions [7][8]. Nutrition - The nutrition segment is currently under pressure, with Q4 sales of $1.94 billion, down 8.9% year-over-year [10][12]. - The decline is attributed to ongoing adjustments in pricing strategies and product mix, which are expected to persist [10][22]. Diagnostics - The diagnostics segment reported Q4 sales of $2.46 billion, a decrease of 2.5% compared to the previous year, primarily due to declining demand for COVID-19 testing [13][15]. - The segment's performance reflects a broader trend of reduced testing needs impacting overall revenue [13][22]. Established Pharmaceuticals - The established pharmaceuticals segment generated Q4 sales of $1.38 billion, maintaining stable growth, particularly in international markets, with a 9.0% increase year-over-year [16][18]. Key Operational Developments - Abbott has received regulatory approval for its first pulse field ablation system for atrial fibrillation patients and has made progress with several cardiovascular and electrophysiology products in Europe [20]. - The company plans to acquire Exact Sciences for approximately $21 billion to expand its oncology screening and diagnostic capabilities [20][21]. 2026 Financial Outlook - For 2026, Abbott's management anticipates accelerated growth driven by new product launches and ongoing business structure optimization [21][22].

Group 1 - The National Development and Reform Commission will hold a press conference on January 26 to discuss the business work and operational situation for 2025 [1] - The National Health Commission will hold a press conference on January 26 to introduce the promotion of the Sanming medical reform experience and the development of traditional Chinese medicine [2] - The 19th Asian Financial Forum will take place from January 26 to 27, focusing on how high-growth industries impact the global economy, including sectors like fintech, healthcare technology, new energy, artificial intelligence, and green technology [3] Group 2 - On January 26, a total of 8 companies will have their restricted shares unlocked, with a total of 164 million shares and a market value of 4.449 billion yuan based on the latest closing price [4] - Among the companies, Yifang Bio-U, Ophtai, and Yuntian Lifei-U have the highest unlock volumes, with 161 million shares, 952,100 shares, and 776,700 shares respectively [4] - Yifang Bio-U, Rongchang Bio, and Yuntian Lifei-U have the highest unlock market values, at 4.251 billion yuan, 78.4656 million yuan, and 67.5979 million yuan respectively [4] Group 3 - Two companies disclosed stock repurchase progress on January 26, with one company announcing a new repurchase plan exceeding 100 million yuan [5] - Zhongchong Co. plans to repurchase up to 200 million yuan worth of shares, while Kaifa Electric has completed a repurchase amounting to 31.7282 million yuan [5] Group 4 - One company announced a private placement on January 26, with one plan being halted [6] Group 5 - One A-share will undergo stock rights registration on January 26, with Xiyi Co. declaring the highest dividend of 1.10 yuan per 10 shares [7] Group 6 - Economic data including the Dallas Fed Business Activity Index for January and Germany's IFO Business Climate Index will be released [8]

Group 1 - The stock price of Jindalai (688057) closed at 12.65 yuan on January 9, 2026, reflecting a 3.52% increase from the previous week's price of 12.22 yuan [1] - The highest intraday price for Jindalai on January 9 was 12.71 yuan, while the lowest intraday price on January 5 was 12.23 yuan [1] - Jindalai's current total market capitalization is 3.491 billion yuan, ranking 70th out of 106 in the environmental governance sector and 4329th out of 5182 in the A-share market [1] Group 2 - The company plans to invest 280 million yuan in Jici Medical, acquiring a 34.00% stake, focusing on autologous cell technology research and development [2] - Jindalai is also increasing its investment in Zhongke Hongtai to enter the vascular interventional surgical robot field, with products currently undergoing special review procedures for national innovative medical devices [2]

Company Overview - Alphatec Holdings specializes in advanced spinal surgery systems, including neural monitoring, fixation, and implant technologies, as well as biologics and imaging products [7][8] - The company generates revenue primarily through the direct sale and distribution of proprietary medical devices and surgical solutions for spinal disorder treatments, targeting hospitals, surgeons, and healthcare providers in the U.S. [7][8] - For the trailing twelve months (TTM), Alphatec reported revenue of $728.02 million and a net income loss of $154.96 million [4] Recent Insider Activity - Scott Lish, the Chief Operating Officer, sold 19,900 shares for approximately $390,836 on December 16, 2025, which represents a 3.01% decrease in his direct holdings, leaving him with 641,432 shares post-sale [1][2][6] - The sale aligns with Lish's median trade size and reflects a consistent selling pattern amid strong share price appreciation [6] Market Performance - Alphatec's shares experienced a 127.08% price change over the past year, with a notable total return of 108.7% [4][6] - The stock reached a 52-week high of $22.66 on November 26, significantly up from a low of $8.81 in April [10] - The company's third-quarter revenue of $197 million marked a 30% year-over-year increase, with a gross margin of 70% [11] Investment Considerations - Despite the insider selling, the transaction does not raise concerns as Lish retains a substantial number of shares [9] - The current price-to-sales ratio of over four indicates a favorable market environment for selling shares, especially given the company's trajectory towards profitability [10][11] - Investors are advised to consider waiting for a potential drop in share price before making new investments in Alphatec [12]

Core Viewpoint - Yunnan Yibao Medical Technology Co., Ltd. has been established with a registered capital of 3 million RMB, fully owned by Yibao Technology (Shanghai) Co., Ltd. [1] Company Information - The legal representative of Yunnan Yibao Medical Technology Co., Ltd. is Luo Han [1] - The registered capital of the company is 3 million RMB [1] - The company is located in Hongshan South Road Community, Wuhua District, Kunming City, Yunnan Province [2] - The company is classified as a limited liability company (sole proprietorship) [2] - The business license allows the company to operate until December 24, 2025, with no fixed term thereafter [2] Shareholder Information - Yibao Technology (Shanghai) Co., Ltd. holds 100% of the shares in Yunnan Yibao Medical Technology Co., Ltd. [2] Business Scope - The business scope includes medical research and experimental development, technical services, technology development, consulting, and transfer [2] - Additional services include internet data services, enterprise management consulting, information system integration, electronic product sales, and software development [2] - The company is also involved in health services, remote health management, and health consulting (excluding diagnostic services) [2] - Certain activities require approval from relevant authorities, including internet information services and medical device internet information services [2]

Company Overview - Jiangxi Dili Medical Technology Co., Ltd. has been established with a registered capital of 1 million RMB [1] - The legal representative of the company is Zhang Lan [1] Business Scope - The company is authorized to operate third-class medical devices, subject to approval from relevant authorities [1] - It also engages in the sale and rental of second-class and first-class medical devices [1] - Additional business activities include domestic trade agency, technical services, development, consulting, and technology transfer [1] - The company is involved in the sale of electronic products, computer hardware and software, communication equipment, and instruments [1] - Information technology consulting and general information consulting services are also part of its operations [1]